advertisement
Abstract #77146 Published in IGR 19-3
Drug-induced Subacute Cutaneous Lupus Erythematosus Caused by a Topical Beta Blocker - Timolol
Bilewicz-Stebel M; Miziołek B; Bergler-Czop B; Stańkowska AActa Dermatovenerologica Croatica 2018; 26: 44-47
Drug-induced lupus erythematosus (DI-LE) is an autoimmune condition secondary to a recent pharmacological intervention. There are no established specific diagnostic criteria for DI-LE, and the disease is recognized based on the medical history of the patient. Typically, the onset is closely related to a recent drug exposure, and the disease terminates after discontinuation of the inducing factor. The most frequent form of DI-LE is drug-induced subacute cutaneous lupus erythematosus (DI-SCLE). There has been an increasing number of drugs which are suspected to provoke SCLE lesions. Previously, systemic beta-blockers (antiarrhythmics and antihypertensives) were shown to be inducing factors of SCLE, however data regarding its topical usage are lacking in the literature. We present the case of a 78-year-old woman who developed annular polycyclic erythema in sun-exposed areas of the skin, four weeks after an initiation of topical timolol treatment of glaucoma. A resolution of cutaneous manifestations within only a few weeks after a cessation of the agent confirmed a clinical suspicion of drug-induced SCLE.
Monika Bilewicz-Stebel, MD Department of Internal Medicine, Dermatology and Allergology, Curie-Skłodowskiej 10, 41-800 Zabrze, Poland, School of Public Health Medical University of Silesia in Katowice 40-027 Katowice, Poland; bil.ste@hotmail.com.
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
9.4.15 Glaucoma in relation to systemic disease (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders)